Mar 04, 2015 at 15:10 | Source: Moneycontrol.com
Shares of Sun Pharmaceutical Industries and Sun Pharma Advanced Research Company (SPARC) rallied 9-10 percent intraday on Wednesday to hit record highs of Rs 1,035 and Rs 448.80, respectively. SPARC, the subsidiary of pharma major, has received approval from US Food and Drug Administration (USFDA) for antiepileptic drug.
Mar 04, 2015 at 15:02 | Source: Moneycontrol.com
Stempeutics Research, a group company of Manipal Education and Medical Group and a Joint Venture with Cipla Group, announced today that the United States Patent and Trademarks Office (USPTO) granted a US process patent for its novel stem-cell based drug Stempeucel.
Mar 04, 2015 at 12:00 | Source: Moneycontrol.com
Sun Pharma topped the buying list on Sensex, up 6 percent. Even its subsidiary Sun Pharma Advanced Research Company gained 6 percent on getting US FDA nod for Elepsia XR extended release tablets, an anti-epileptic drug. SPARC says product will be manufactured by Sun Pharma at Halol unit.
Mar 04, 2015 at 10:13 | Source: Moneycontrol.com
Sun Pharma Advanced Research Company today announced that the USFDA has approved its New Drug Application (NDA) for ELEPSIA XRTM (Levetiracetam extended-release tablets 1000 mg and 1500 mg). ELEPSIA XRTM is indicated for adjunctive therapy in the treatment of partial onset seizures in patients 12 years of age and older with epilepsy.
Mar 03, 2015 at 16:49 | Source: PTI
The DC Federal Court in the US has upheld the decision of the USFDA for rescinding tentative approvals given to it for generic digestive disorder drug Nexium and antiviral Valcyte.
Mar 02, 2015 at 20:15 | Source: PTI
As on December 31, 2014, the company had a total of 781 filings for formulations of which 333 have been approved in various regions globally.
Mar 02, 2015 at 17:10 | Source: Moneycontrol.com
Concord Drugs has reported a sales total income from operations of Rs 10.11 crore and a net profit of Rs 0.13 crore for the quarter ended Dec '14
Mar 02, 2015 at 16:11 | Source: Moneycontrol.com
Jubilant Life Sciences has received Abbreviated New Drug Application (ANDA) final approval from the US Food and Drug Administration (USFDA) for Montelukast Sodium Chewable Tablets, 4 mg and 5 mg, the generic version of Singulair Chewable Tablets (of Merck), which is used for the treatment of asthma and to relieve symptoms of seasonal allergies.
Mar 02, 2015 at 13:35 | Source: Reuters
Natco will fix its own price for the generic versions, and will pay a royalty on sales to Gilead, the company said.
Mar 02, 2015 at 10:48 | Source: Moneycontrol.com
Dr Datsons Labs and AL-MUGDH PHARMA of Yemen have singed a licensing, distribution and supply deal, under which the distribution company will market Anti-Malarial drugs.